NCT06604611View on ClinicalTrials.gov

Colchicine in Patients with Heart Failure with Preserved Ejection Fraction and Inflammation

PHASE4Not yet recruitingINTERVENTIONAL
Enrollment

200

Participants

Timeline

Start Date

October 31, 2024

Primary Completion Date

December 31, 2025

Study Completion Date

March 31, 2026

Conditions
Heart FailureHeart Failure with Preserved Ejection Fraction (HFPEF)Chronic InflammationInflammationColchicine
Interventions
DRUG

Colchicine 0.5 MG Oral Tablet Once Daily

The intervention in this study is colchicine, patients randomized to the experimental group will be given oral colchicine 5mg once a day in 12 weeks.

Trial Locations (1)

400000

The First Affiliated Hospital of Chongqing Medical University, Chongqing

All Listed Sponsors
collaborator

National Natural Science Foundation of China

OTHER_GOV

lead

Dongying Zhang

OTHER

NCT06604611 - Colchicine in Patients with Heart Failure with Preserved Ejection Fraction and Inflammation | Biotech Hunter | Biotech Hunter